Meridian Bioscience Inc. (NASDAQ:VIVO) is expected to report fourth quarter earnings results, before market open, on Friday 13th November 2020.
Analysts polled by Thomson Reuters anticipate fourth quarter income of $ 0.14 per share.
Looking ahead, the full year income are expected at $ 1.02 per share on the revenues of $ 249.15 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 245.00 million ~ $ 250.00 million, where as bottomline are predicted in a range of $ 1.01 ~ $ 1.05 per share
Click Here For More Historical Outlooks Of Meridian Bioscience Inc.
Previous Quarter Performance
Meridian Bioscience Inc. came out with income for the third quarter of $ 0.55 per share, from the revenue of $ 84.80 million. The quarterly earnings improved 243.75 percent compared with the same quarter last year. Wall street analysts are predicting, VIVO to report 3Q20 income of $ 0.23 per share from revenue of $ 66.04 million. The bottom line results beat street analysts by $ 0.32 or 139.13 percent, at the same time, top line results outshined analysts by $ 18.76 million or 28.41 percent.
Stock Performance
Shares of Meridian Bioscience Inc. traded low $ -0.34 or -2.06 percent on Thursday, reaching $ 16.17 with volume of 540.30 thousand shares. Meridian Bioscience Inc. has traded high as $ 16.82 and has cracked $ 15.93 on the downward trend
According to the previous trading day, closing price of $ 16.17, representing a 199.64 % increase from the 52 week low of $ 5.51 and a 37.89 % decrease over the 52 week high of $ 26.58.
The company has a market capital of $ 693.09 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Meridian Bioscience Inc. will be hosting a conference call at 10:00 AM eastern time on 13th November 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, (866) 443-5802 Toll Free or (513) 360-6924 Outside U.S., when prompted, enter passcode 3958286 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.meridianbioscience.com
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT!
